Germany’s drug assessment body said data provided by Bayer on the precision cancer drug Vitrakvi did not provide clear enough evidence of benefits, in a setback to the drugmaker in the company’s home market.

For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.

The European Commission approved Astellas Pharma’s oral once-daily therapy Xospata as a monotherapy for treating adults with relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

U.S. federal agents executed a warrant to search the Clio Laboratories in Georgia as part of a nationwide crackdown into genetic testing fraud against federal health insurance programs.

In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.

Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.

The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.

The U.S. Food and Drug Administration lifted a partial clinical hold placed on AbbVie’s Phase III CANOVA trial evaluating venetoclax for the treatment of relapsed/refractory multiple myeloma.

Columbia Care Inc. announced the initiation of a research study designed to optimize the use of the company’s precisely manufactured, pharmaceutical-quality medical cannabis products through the identification of genetic factors affecting their safety and efficacy.

The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.